Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07195175
Recruiting Phase 1

Study of MAR002 in Healthy Men

NCT07195175 · tracked via the Priya Life Science USA tracker
Sponsor
Marea Therapeutics
Phase
Phase 1
Started
2025-08-11
Last updated
2026-01-12

Condition(s) studied

Acromegaly

Investigational drug(s) / intervention(s)

MAR002 →Placebo

MAR002: subcutaneous injection

Placebo: Subcutaneous injection

Study summary

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

Eligibility

Sex
MALE
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Willingness to provide written informed consent 2. Age 18 to 40 3. Weight 55 to 95 kg 4. Body mass index (BMI) 18 to 30 kg/m2 5. Healthy men Exclusion Criteria: 1. History of hypersensitivity to monoclonal antibodies or study drug 2. Participation in any other investigational drug study 3. History of cancer 4. Recent acute illness 5. Positive test for HIV, hepatitis B/C 6. History of substance abuse or nicotine use 7. Recent blood donation 8. History of pituitary disorder 9. Any condition that prevents the participant from complying with study procedures

Primary outcome measure(s)

  • Number of participants with TEAEs (treatment-emergent adverse events) — From first dose of study drug through final End of Study/Early Termination Visit. End of Study is Day 64 for Cohorts 1 and 2; End of Study is day 169 for Cohorts 3, 4, 5, and 6.
    To evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

Trial sites (1)

FacilityCityRegionStatus
Marea Site Tempe Arizona Recruiting

More Marea Therapeutics trials in the USA

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Recruiting
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Recruiting
A Study to Evaluate MAR002 for Acromegaly Recruiting

Other trials for the same condition

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs Recruiting
A Study to Evaluate MAR002 for Acromegaly Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07195175 on ClinicalTrials.gov ↗ ← All trials in the USA